Muscle Growth & Hormone OptimizationFDA Approved

Tesamorelin

Tesamorelin (Egrifta)

The only FDA-approved GHRH analog, clinically proven to reduce visceral fat by 15-20% while preserving lean mass.

4 studies referencedVisceral fat reduction and growth hormone optimization through natural pituitary stimulation

Tesamorelin is a synthetic form of growth hormone releasing hormone (GHRH) consisting of 44 amino acids that match the full sequence of natural human GHRH, with one important modification: a trans-3-hexenoic acid group attached to the N-terminus that makes it more stable and resistant to breakdown. It was developed by Theratechnologies, Inc. of Canada and received FDA approval in 2010 under the brand name Egrifta for reducing excess abdominal fat in adults with HIV who have lipodystrophy. A newer formulation called Egrifta WR was approved in 2024, offering weekly reconstitution instead of daily.

Tesamorelin has been called the visceral fat peptide, and it is the most expensive growth hormone related peptide option available. It works through the same mechanism as CJC-1295 and Sermorelin, stimulating your pituitary gland to produce and release its own growth hormone rather than replacing it with synthetic hormone. This approach preserves the natural pulsatile pattern of growth hormone secretion and maintains your body's feedback mechanisms. The result is a more natural hormone profile compared to injecting growth hormone directly.

Beyond its approved use, researchers have studied tesamorelin for conditions including obesity, nonalcoholic fatty liver disease (NAFLD), insulin resistance, and cognitive function in older adults. What makes tesamorelin unique is not a different mechanism but rather the specific clinical data behind it. The HIV lipodystrophy trials specifically measured visceral fat reduction with CT scans over 26 weeks, which is what earned its FDA approval. Other GHRH analogs were not studied that way, so the comparison data simply does not exist yet.

How It Works

Tesamorelin works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. When these receptors are activated, they trigger a signaling cascade that results in your pituitary gland synthesizing and releasing your own growth hormone. It mimics the GHRH signal from your hypothalamus while maintaining your natural feedback loops and pulse pattern. After injection, tesamorelin absorbs rapidly with peak blood concentration happening about 30 minutes to an hour later. The half-life is only about 26 minutes, so it clears fast, but it creates a two to three hour growth hormone burst from your pituitary.

Once growth hormone is released into your bloodstream, it travels to your liver where it is converted into IGF-1 (insulin-like growth factor 1). IGF-1 is what actually does most of the work: fat mobilization, muscle repair, recovery, collagen production, and bone density maintenance. For your liver to efficiently convert growth hormone into IGF-1, you need insulin present. This creates a natural paradox that your body solves with timing: you sleep fasted for maximum growth hormone release, then eat in the morning to provide the insulin needed for IGF-1 conversion.

Tesamorelin is often paired with GHRPs like Ipamorelin because they hit different pathways. Tesamorelin stimulates the GHRH pathway while Ipamorelin mimics the ghrelin pathway. When both are activated simultaneously, the combined signal produces a much larger growth hormone pulse than either one alone. The GHRP suppresses somatostatin (which normally inhibits growth hormone release) while the GHRH drives pituitary output, creating a powerful synergistic effect.

Potential Benefits

Visceral Fat Reduction

Clinical trials demonstrate tesamorelin reduces visceral adipose tissue by approximately 15 to 20 percent over 26 weeks. This effect specifically targets the deep abdominal fat most associated with cardiovascular and metabolic disease risk. Visceral fat is the dangerous fat that surrounds your organs and is linked to heart disease, diabetes, and other serious health conditions.

Preservation of Lean Mass

While reducing fat, tesamorelin helps preserve lean body mass. This makes it valuable during cutting phases or caloric restriction when muscle loss is a concern. Growth hormone promotes protein synthesis and opposes the catabolic effects of dieting, meaning you lose fat without sacrificing the muscle you have worked hard to build.

Improved Lipid Profile

Studies show tesamorelin improves triglyceride levels and the ratio of total cholesterol to HDL cholesterol. In the HIV trials, triglycerides dropped by about 50 points on average and cholesterol reduced by about 30 percent. These improvements in blood fats may reduce cardiovascular risk factors associated with excess visceral fat.

Liver Health Support

Research in patients with nonalcoholic fatty liver disease shows tesamorelin reduces hepatic fat content by approximately 37 percent. It may also prevent progression of liver inflammation and fibrosis. This represents a promising application beyond its approved indication, as fatty liver disease affects millions of people worldwide.

Cognitive Function

A study published in JCI Insight showed tesamorelin improved cognitive function and brain metabolism in older adults at risk for Alzheimer's disease. Other research suggests improvements in executive function, working memory, and response inhibition in older adults, including those with mild cognitive impairment. IGF-1 crosses the blood-brain barrier and appears to have protective effects when restored to mid-normal levels.

Enhanced Recovery

Elevated growth hormone and IGF-1 support collagen turnover, joint integrity, and soft tissue repair. Athletes and active individuals may experience improved recovery from training and injury. IGF-1 drives muscle protein synthesis, collagen production, and bone density maintenance.

Natural Hormone Stimulation

By working through the body's own GHRH receptors, tesamorelin maintains physiological feedback mechanisms. This results in more natural growth hormone pulsatility compared to direct growth hormone injections, keeping your pituitary gland active and functional rather than suppressing it.

What the Research Shows

FDA Approved

Falutz and colleagues published a pivotal Phase III trial in 2010 in the Journal of Acquired Immune Deficiency Syndromes, evaluating tesamorelin in 404 HIV-infected patients with excess abdominal fat. Tesamorelin reduced visceral adipose tissue by approximately 18 percent compared to placebo, improved body image distress scores significantly, and did not cause significant perturbation of glucose metabolism. However, effects reversed when treatment was discontinued, with some fat reaccumulation occurring over time.

Grunfeld and colleagues published results in the New England Journal of Medicine in 2007, assessing 412 HIV patients receiving either 2 mg tesamorelin or placebo daily for 26 weeks. Tesamorelin significantly decreased visceral fat by 15 to 20 percent measured by CT scan, preserved lean body mass during fat loss, dropped triglycerides by about 50 points on average, reduced cholesterol by about 30 percent, and raised IGF-1 levels into the mid-normal range. Overall glucose tolerance was not worsened, and some patients with fatty liver disease saw significant improvements.

Stanley and colleagues published a randomized, double-blind multicenter trial in 2019 examining tesamorelin in people with HIV and nonalcoholic fatty liver disease. Tesamorelin reduced hepatic fat fraction by 37 percent, prevented liver fibrosis progression compared to placebo, and maintained benefits over 12 months of treatment. Additionally, a study published in JCI Insight showed tesamorelin improved cognitive function and brain metabolism in older adults at risk for Alzheimer's disease, with research suggesting improvements in executive function, working memory, and response inhibition.

What to Know

CommonImportantSerious

Injection site reactions including redness, swelling, pain, itching, and flushing are very common, lasting about 10 to 20 minutes after injection. Joint pain (arthralgia), muscle pain (myalgia), peripheral edema with mild fluid retention, and tingling or numbness sensations are also frequently reported.

Tesamorelin may cause glucose intolerance and increase blood sugar in some individuals, particularly those who are pre-diabetic or have insulin resistance. It may increase the risk of type 2 diabetes in predisposed individuals. Elevated IGF-1 levels require monitoring during treatment. Do not use alongside exogenous growth hormone or IGF-1, as research showed GHRH pathway compounds were inhibited by 86 percent after a single exogenous GH injection.

Tesamorelin raises IGF-1 levels, which theoretically could stimulate growth of existing tumors. Individuals with active cancer, history of any malignant tumor, pituitary gland disorders, or history of radiation therapy to the head should not use tesamorelin. It is FDA Pregnancy Category X, meaning it can harm the fetus. Hypersensitivity reactions including rash, hives, and difficulty breathing require immediate discontinuation.